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Abstract
Background: Concerns about the safety of paralytics such as succinylcholine to facilitate endotracheal intubation limit their
use in prehospital and emergency department settings. The ability to rapidly reverse paralysis and restore respiratory drive
would increase the safety margin of an agent, thus permitting the pursuit of alternative intubation strategies. In particular,
patients who carry genetic or acquired deficiency of butyrylcholinesterase, the serum enzyme responsible for
succinylcholine hydrolysis, are susceptible to succinylcholine-induced apnea, which manifests as paralysis, lasting hours
beyond the normally brief half-life of succinylcholine. We hypothesized that intravenous administration of plant-derived
recombinant BChE, which also prevents mortality in nerve agent poisoning, would rapidly reverse the effects of
succinylcholine.
Methods: Recombinant butyrylcholinesterase was produced in transgenic plants and purified. Further analysis involved
murine and guinea pig models of succinylcholine toxicity. Animals were treated with lethal and sublethal doses of
succinylcholine followed by administration of butyrylcholinesterase or vehicle. In both animal models vital signs and overall
survival at specified intervals post succinylcholine administration were assessed.
Results: Purified plant-derived recombinant human butyrylcholinesterase can hydrolyze succinylcholine in vitro. Challenge
of mice with an LD100 of succinylcholine followed by BChE administration resulted in complete prevention of respiratory
inhibition and concomitant mortality. Furthermore, experiments in symptomatic guinea pigs demonstrated extremely rapid
succinylcholine detoxification with complete amelioration of symptoms and no apparent complications.
Conclusions: Recombinant plant-derived butyrylcholinesterase was capable of counteracting and reversing apnea in two
complementary models of lethal succinylcholine toxicity, completely preventing mortality. This study of a protein antidote
validates the feasibility of protection and treatment of overdose from succinylcholine as well as other biologically active
butyrylcholinesterase substrates.
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Introduction
Rapid sequence intubation (RSI) combines a sedative and a
neuromuscular blocking agent (NMBA) to prepare a critically ill
patient for emergent intubation [1,2]. RSI is considered a safe
procedure in the well-controlled environment of the emergency
department where a large, diverse and highly trained team is
available to provide emergent intubation, and where increased
safety is bolstered by the availability of a large variety of rescue
devices [3]. In the pre-hospital arena, the role of RSI remains,
however, controversial [4,5,6,7]. While some studies have
demonstrated benefit, particularly in specific groups such as head
injury patients, other authorities stress the complexity of this
procedure, the risks associated with inadequately qualified, trained
and equipped personnel and the overall lack of large-scale risk-
benefit validation [5,6,7,8,9]. The controversy is well-reflected in
the official policy statement of the American College of
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Emergency Physicians (ACEP), which declares that it ‘‘is not an
advocacy statement for or against the use of’’ RSI [8].
Furthermore, disagreement exists over the ideal NMBA, but
frequently centers on the non-depolarizing NMBA rocuronium
and the depolarizing NMBA succinylcholine (SC, suxamethoni-
um)[10,11]. Of the two, consensus generally leans towards
succinylcholine due to increased control afforded by the much
shorter half-life, unless a contraindication exists [12,13,14].
Obvious contraindications include hyperkalemia, allergy, history
of malignant hyperthermia, denervation syndromes or recent burn
or crush injury. A more occult contraindication is delayed
metabolism through the genetic absence of the SC hydrolyzing
enzyme butyrylcholinesterase (BChE, plasma cholinesterase,
pseudocholinesterase)[15].
This condition, succinylcholine apnea, is believed to exist in 1 in
1800 administrations of SC[16]. Of these, approximately 65% are
caused by decreased SC hydrolysis by BChE variants with
decreased hydrolytic function or decreased protein stability
leading to lower effective serum levels[17]. Individuals who are
homozygous in respect to the ‘‘atypical’’ (A) variant of the BChE
gene (D70G, residual serum BChE activity is ,30% of
normal)[18,19] experience periods of apnea of approximately 2
hours upon receiving an i.v. dose of SC that would otherwise result
in only 3–5 minute-long paralysis in people with the common or
‘‘usual’’ (U) allele [17,20]. Homozygocity toward several (,48)
other mutations in the BCHE locus lead to an even more drastic
phenotype. These ‘‘silent’’ (S) variants of BChE and the affected
patients are apneic for a much longer duration of 3–4 hours or
even longer [17,21]. While patients homozygous in respect to
either the A or S variants are rare among the general population
(,0.03% and,0.01% respectively), heterozygotes are much more
common (4% of the general population carry at least one A allele)
and exhibit varying degrees of post-SA apnea depending on their
specific combination of alleles and in direct correlation with their
serum BChE activities [17].
The remaining cases of BChE deficiency are acquired through
conditions decreasing circulating hepatoproteins such as cirrhosis
[22], burns [23,24], HELLP (hemolysis, elevated liver enzymes
and low platelet count) syndrome [25], hepatic carcinoma [26]
and malnutrition [27]. Furthermore, functional BChE deficiency
can be acquired through the use of commonly prescribed drugs
affecting production or function of BChE such as oral contracep-
tives [28], sertraline[29], cyclophosphamide[30,31,32], tac-
rine[33], phenelzine[34], bambuterol[35], metoclopramide[36],
and ecothiophate[37,38]. Beyond the rare case of genetic or
acquired SC apnea, the ability to rapidly reverse the effects of SC
could provide a significantly increased safety margin for the agent
by allowing the return of spontaneous respirations and the pursuit
of other management strategies including alternative medications
and airway devices. This is particularly true in cases of upper
airway obstruction where neuromuscular blockade carries the risk
of airway collapse [39].
Current management approaches for post-SC apnea, a typically
self-limiting condition, are supportive and highly resource
intensive[40], mainly because of the lack of effective reversal
agents. Anticholinesterases such as edrophonium and neostigmine,
presumably intended to overcome cholinergic blockade by raising
synaptic levels of acetylcholine, have been tested with under-
whelming results [41]. The missing or nonfunctional serum BChE
can be replaced by the active U-variant of the enzyme present in
blood products like stabilized serum [42], fresh frozen plasma [43]
or the purified enzyme (previously available for human use in
Europe, but currently discontinued) [44] but the treatment carries
the usual risks of blood-borne pathogens and prions, as well as the
more common transfusion associated complications, including
transfusion-related acute lung injury (TRALI)[45].
To take advantage of recent advances in biotechnology, we and
others have hypothesized that purified recombinant human BChE
would serve as an ideal antidote for SC apnea by avoiding risk of
infection, TRALI and supply limitations [46,47,48]. Our group
has previously demonstrated, in both mice and guinea pigs, the
efficacy of recombinant BChE and acetylcholinesterase prophy-
laxis to prevent morbidity and mortality in organophosphate
poisoning [49,50]. These two animal species offer the prediction
power expected of an animal model with small body sizes that
limit the quantities of test materials required and ease of
physiological measurements. Here we report SC hydrolysis and
reversal of apnea and cardiovascular collapse with treatment of
affected mice and guinea pigs by catalytic quantities of BChE.
Materials and Methods
Preparation of recombinant butyrylcholinesterase
Transgenic plants expressing a plant-optimized synthetic gene
encoding full-length wild-type human BChE were created as
previously described [51]. Briefly, stable Nicotiana benthamiana lines
expressing a codon-optimized human butyrylcholinesterase were
created and screened for maximal expression. The lines with
highest accumulation were expanded from homozygous seed
stocks and propagated under greenhouse conditions. Plant-derived
BChE (pBChE) was prepared from mature 8–11 week old plants
that were juiced in the presence of 150 mM sodium metabisulfite,
and the juice was strained and clarified by centrifugation. The
30%–70% ammonium sulfate fraction (pH 4.0) was resuspended
and subjected to two affinity chromatography steps, first through
Concanavalin A-Sepharose 4B and then procainamide-agarose gel
custom resin. Eluate was dialyzed against 0.1256 phosphate-
buffered saline (PBS), pH 7.4, then concentrated and stored with
0.02% azide at 4uC for up to 6 months. Prior to use, the
preparation was dialyzed again against.1256 PBS to remove
azide. As previously described, our preparations of plant-derived
BChE contain mostly tetramers (about a half) and monomers
(about a third) [50].
Biochemical analysis
Assay of butyrylthiocholine hydrolysis followed the method of
Ellman as described in [51]. Succinylcholine hydrolase activity was
monitored by the method of George and co-workers [52] with
modifications to fit a 96-well plate format. Briefly, our standard
succinylcholine-hydrolysis buffer contained 100 mM NaH2PO4/
Na2HPO4 buffer pH 7.5, 0.77 mM phenol, 0.15 mM 4-aminoan-
tipyrine, 1 U/mL choline oxidase, and 1.2 U/mL horse radish
peroxidase type I. Appropriate volumes of 106 stock solutions (in
100 mM NaH2PO4/Na2HPO4 buffer pH 7.5) were pre-mixed
and dispensed at 160 mL aliquots onto 96-well plates followed by
addition of the substrate succinylcholine chloride (20 ml, final
concentrations as indicated). Reactions were started by addition of
pBChE (4.74 nM) to yield a final well volume of 200 ml.
Hydrolysis was monitored by recording absorbance changes at
500 nm. Self hydrolysis rates were measured on samples that
contained no enzyme and were subtracted from the enzymatically
catalyzed reaction rates. A choline standard curve was similarly
created by using the same assay except that choline chloride
replaced succinylcholine (final concentration range of 10–
100 mM).
Kinetic analysis was done according to Radic´ et al. [53] as
follows. Initial enzyme velocity, V0, was plotted as a function of
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substrate concentration and the results were fitted by nonlinear
regression using GraphPad Prism to the following equation:
where [SC] is the concentration of SC, Vmax is maximal
velocity, KM is the Michaelis-Menten constant, KSS is the
dissociation constant of substrate from the enzyme’s peripheral
binding site, and b is a factor that reflects the efficiency of
hydrolysis of the substrate in the presence of another substrate
molecule bound at the peripheral site (with substrate activation
when b.1).
In vivo experiments
All animal experiments were conducted in accordance to
specific protocols approved by the Institutional Care and Use
Committee of Arizona State University (approval number 07-
911R).
Mouse experiments were conducted as follows. Male FVB/N
mice (Mus musculus, 8–12 weeks old) were anesthetized by injection
of ketamine/xylazine/acepromazide cocktail at the dose of
0.05 mL per 25 g of total body weight (concentrations were,
respectively 21 mg/mL, 2.4 mg/mL, and 0.3 mg/mL). Anesthe-
tized mice were assessed for respiratory rate by counting
respirations for 30 seconds using a Littman model 3000 electronic
stethoscope placed on the mouse left mid axillary line and
extrapolating the per minute rate. Mice were then injected
intravenously (tail vein) with 1 mg/kg succinylcholine (time
0 min). At time +3 min mice were injected with pBChE
(0.6 mg/kg, ,11 U per animal, n=3) in 0.9% saline (or 0.9%
saline vehicle control, n=3) and respiratory rate was obtained as
above at the indicated time points. At time +15 minutes all
surviving mice were euthanized by CO2 asphyxiation and
subsequent cervical dislocation. At no time during the experiment
did the mice receive any other therapy including, but not limited
to, airway protection/management, artificial ventilations, com-
pressions, or any pharmacological assistance.
Guinea pig experiments were conducted as follows. Male
Hartley guinea pigs (Cavia porcellus, 8 weeks old) were anesthetized
with 90 mg/kg ketamine and 10 mg/kg xylazine. Once anesthe-
tized, baseline heart rate (beats per minute) and SpO2 (%) were
obtained using a Surgivet Plus Veterinary Anesthesia and
Monitoring Module, model #V3404. Guinea pigs (3 per group)
were then intravenously (leg vein) injected at t = 0 with SC at
either low dose (0.167 mg/kg, experiment I) or a high dose
(0.334 mg/kg, experiment II). Heart rate and SpO2 were obtained
every minute throughout the course of the experiment. At time
+1 min, groups of three apneic guinea pigs were injected with
either pBChE in 0.9% saline at a low dose (0.09 mg/kg, ,24 U
per animal, experiment I), high dose (0.19 mg/kg, ,48 U per
animal, experiment II), or 0.9% saline vehicle control (experiment
I and II). At t = +15 minutes, all surviving guinea pigs were
euthanized by CO2 asphyxiation and subsequent cervical disloca-
tion. As above, guinea pigs received no additional care or therapy
during experimentation.
Statistical analyses
Statistical analyses were carried out using the GraphPad Prism
software. Log-rank (Mantel-Cox) test was used to determine
significance of the difference between survival curves. Compari-
sons between mean values of heart rate and Sp02 were tested using
1-way analysis of variance (ANOVA) followed by Bonferroni’s
Multiple Comparison Test. Results were also analyzed by 2-way
ANOVA (testing simultaneous effects of time and BChE
treatment) and simple t-tests, and the inferences based on these
analyses were very similar to those obtained by the 1-way ANOVA
analysis described above.
Results
Initial characterization of plant-derived, recombinant human
butyrylcholinesterase (pBChE) was previously published and was
found to be indistinguishable from that of the human plasma-
derived enzyme in its ability to interact with its acetylcholine and
butyrylcholine substrates and various inhibitors [50,51,54]. These
studies included detailed in-vitro and in-vivo demonstration of the
ability of the plant-derived enzyme to scavenge organophosphate
pesticides and nerve-agents (‘‘nerve gasses’’). Here we extend these
studies in order to investigate the potential of pBChE to reverse
SC-induced apnea and therefore determined its SC hydrolytic
capacity. Succinylcholine hydrolysis by pBChE proceeded in a
linear time-dependent manner with BChE (data not shown)
allowing us to calculate the initial enzyme velocity (V0).
Conducting the experiment at increasing SC concentrations and
plotting the V0 values as a function of the SC concentration (Fig. 1)
allowed us to obtain the Michaelis constant (KM=5767 mM) and
the turnover number (kcat = 516633 min
21, Fig. 1). The catalytic
efficiency (kcat/KM) was calculated to be 9610
6 M21min21. These
values were consistent with previously published results for human
BChE (KM=35 mM and kcat = 600 min
21)[55]. Differences might
be attributed to the difference in the assay used in the published
research that employed an SA thioester analog. As is the case with
many other substrates of BChE, hydrolysis of SC by the enzyme
was shown to exhibit substrate activation, presumably due to
allosteric interactions involving the peripheral substrate binding
site.
To test our study’s hypothesis that pBChE could reverse
succinylcholine-induced apnea, we turned to animal-models in two
species. Initial studies were conducted with mice that were
administered intravenous SC, 1 mg/kg, a dose which constituted
about.36LD50 (0.28 mg/kg) [56] and in our hands proved to be
lethal to 100% of tested animals. Mice were then randomized to
receive either 15 U BChE or vehicle control (0.9% saline) at 3 min
following SC injection. Respiratory rate was monitored every five
Figure 1. Plant-derived BChE undergoes substrate activation by
its succinylcholine substrate. Blue line represents data fitted by
nonlinear regression to fit the equation:
V0~
1zb½SC=KSS
1z½SC=KSS xVmax
1zKM=½SCwith the following parameters (6SEM): Vmax =
2.4560.16 mM/min, KM= 5767 mM, Kss = 2.060.3 mM, and b= 2.960.1.
kcat = Vmax/[BChE]T was calculated to be 516633 min
21 based on the
above Vmax value and [BChE] = 4.74 nM.
doi:10.1371/journal.pone.0059159.g001
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minutes following SC injection. While all three mice receiving SC
+0.9% saline succumbed to the SC-induced respiratory depression
and subsequently died, all three mice receiving SC+15 U BChE
survived (Fig. 2).
To further understand the effect and kinetics of BChE-mediated
SC detoxification using continuous vital sign monitoring, we
moved to a larger rodent model of SC toxicity. Utilizing guinea
pigs, we intravenously injected groups of three animals with either
0.167 mg/kg (,LD50, Fig. 3) or a larger dose that leads to 100%
mortality (0.334 mg/kg, Fig. 4). Complete apnea and resultant
decreases in oxygen saturation were seen in both groups at 1 min
following SC injection, at which time study animals received either
24 U (Fig. 3), 48 U BChE () or vehicle control (0.9% saline, Fig. 3
and Fig. 4). Animals in all four groups went on to demonstrate an
absence of measurable pulse and oxygen saturation within 2 to
3 min following SC injection (Fig. 3 and 4). Within 2 minutes,
guinea pigs receiving BChE recovered spontaneous respirations,
their venous oxygenation level had risen to about 50% and their
heart rate was at baseline. In fact, median time to recovery was
0.8 min for animals treated with the low dose of SC and 1.7 min
for the high dose of SC. We witnessed a fairly consistent response
of post-anoxic tachycardia in recovering guinea pigs at 5 min post
SC injection, however by 7 min post SC injection all vital signs
had returned to baseline in all animals treated by BChE. In
striking contrast, only two of the three saline-treated control
animals survived with a median time to recovery of 4.8 min. Thus,
control animals experienced slower recovery (median ratio saline/
BChE=6.0, 95% confidence interval of 5.8 to 6.2) following a
low-dose SC exposure. In this case the hazard ratio of BChE-
treated and controls was 15.34 (95% confidence interval of 1.418
to 166.0). Moreover, all animals exposed to high dose of SC
without BChE treatment died without any recovery of viable signs.
At no point following loss of measurable pulse and venous oxygen
saturation did these signs return in animals receiving the high dose
of SC without the treatment +0.9% saline.
Figure 2. Plant-derived BChE protects mice from SC-induced
apnea. A Respiration rate of mice treated with SC followed by
administration of pBChE or saline was monitored. Symbols represent
individual animal subjects (n=3 for each group). B The Kaplan–Meier
estimates of survival reflecting survival of all pBChE-treated mice as
opposed to 100% mortality among control, saline-treated subjects.
Comparison by the Log-rank (Mantel-Cox) test was significant
(P,0.025).
doi:10.1371/journal.pone.0059159.g002
Figure 3. Plant-derived BChE facilitate recovery of guinea pigs
treated with sublethal dose of SC. Guinea pigs were injected with
SC (0.167 mg/kg) followed by injection with BChE (n= 3, red) or saline
(n= 3, blue) while monitoring oxygen saturation (A) and heart rate (B).
Reported data points represent means6SEM. Means at each time point
were compared by 2-way repeated ANOVA and P values are denoted on
the graphs. Statistical analyses by t-test or 1-way ANOVA yielded very
similar results. C Time to return to normal heart rate. Comparison by the
Log-rank (Mantel-Cox) test was significant (P,0.025).
doi:10.1371/journal.pone.0059159.g003
Recombinant BChE Rverses Paralytic-Induced Apnea
PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e59159
Discussion
This study demonstrates the capability of plant-derived recom-
binant human BChE to completely reverse the effects of SC
paralysis and respiratory compromise in two small animal models
where no additional supportive care was provided. Our work
provides a natural extension to previous work that demonstrated
the proof of principle for enzyme replacement therapy to
counteract the effects of profound neuromuscular SC blockade
in patients with BChE deficiencies [42,43,44]. All of these previous
reports centered around the human plasma enzyme, as present in
various blood products or purified from the latter. Plasma-derived
BChE is expensive, exists in greatly limited supply, and is,
consequently, of limited utility. Our work demonstrates, for the
first time, the application of recombinant BChE produced in a
sustainable fashion in plants as an antidote to SC-induced
neuromuscular blockade. Plant-based production platforms as a
source for protein pharmaceuticals are only now beginning to be
tapped into with a recent approval of carrot-cell derived
glucocerebrosidase for the treatment of Gaucher disease [57,58].
Our results provide, in two small animal models, the proof of
principle that SC-induced apnea can be reversed by administra-
tion of plant-produced recombinant human BChE. While our
studies were conducted in small number of animals, they provide
evidence that is statistically significant, for full protection afforded
by the plant-produced enzyme. Additional future tests will aim to
look at more subtle biological outcomes (e.g. immune responses to
the plant-derived biologics), to determine the safety and efficacy
and are likely to require larger number of subjects per group to
yield the necessary power.
The ability to rapidly reverse the effects of SC may have
profound clinical implications in cases ranging from genetic or
acquired SC apnea to SC overdose and particularly traditional
RSI utilizing SC as the paralytic. Failed airways are a relatively
common event in both the emergency department and the
prehospital arena and the decision to adopt an alternate strategy
may be hampered by lingering paralysis and the absence of
spontaneous respirations. While RSI in emergency medical service
is common in some areas, many other agencies have removed
paralytics from the drug box of first responders over concerns of
apnea, prolonged hypoxia and cardiovascular collapse. In addition
to simulation, increased training intervals and close oversight,
pharmacological reversal of SC paralysis may increase the safety
margin associated with RSI in prehospital medicine.
In broad terms, the search for antidotes must balance efficacy
with practicality. While recombinant proteins offer the potential
for rational design and mutation of naturally occurring molecules,
the increased cost and relatively decreased shelf life encourages
exploration of alternate uses for these technologies so they can be
applied toward multiple indications. Treatment of SC-induced
apnea offers an alternative use for recombinant BChE, beyond
scavenging of organophosphate nerve agents in a chemical
warfare/terrorism scenario [47,50,51], that may provide increased
patient safety in the use of RSI in both hospital and pre-hospital
care. Moreover, SC is used in clinical contexts beyond RSI, for
example in conjunction with electroconvulsive therapy, where
BChE variants may have a negative impact as was recently shown
by Mollerup and Ga¨tke [59]. Further potential use of BChE
includes rapid cocaine detoxification in overdose as well as
pharmacological protection of cocaine ‘‘packers’’ during GI
clearance [60,61,62].
Determination of the appropriate agent and venue for RSI must
balance safety and efficacy with continuous measurement of
patient outcomes. The availability of plant-derived BChE to
rapidly clear SC and reverse apnea should add a new facet to the
debate over the ideal paralytic and potentially prevent some of the
more common outcomes of prolonged hypoxia during the
management of difficult airways using SC [10,11,12,13,14].
Beyond the rare case of genetic or acquired SC apnea, the ability
to rapidly reverse the effects of SC could provide a significantly
increased safety margin for the agent by allowing the return of
spontaneous respirations and the pursuit of other management
Figure 4. Plant-derived BChE fully protects guinea pigs from
high-dose SC-induced apnea. Guinea pigs were injected with SC
(0.334 mg/kg) followed by injection with BChE (n=3, red) or saline
(n=3, blue) while monitoring oxygen saturation (A) and heart rate (B).
Reported data points represent means6SEM. Means at each time point
were compared by 2-way repeated ANOVA and P values are denoted on
the graphs. Statistical analyses by t-test or 1-way ANOVA yielded very
similar results. C Time to return to normal heart rate. Comparison by the
Log-rank (Mantel-Cox) test was significant (P,0.025).
doi:10.1371/journal.pone.0059159.g004
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strategies including alternative drugs and airway devices. While we
acknowledge that a reversal drug to remove excess SC leading to
neuromuscular blockade is only one aspect of a much more
complicated clinical scenario, we hope that the preclinical work
presented would revive interest in testing plant-derived BChE as a
tool to counteract SC-induced paralysis in a clinical setting. Such a
clinical trial will have to take place following Phase I trials to
demonstrate safety of this protein drug. Work at our lab continues
toward this goal.
Conclusions
In two complementary small animal models of succinylcholine-
induced apnea, recombinant butyrylcholinesterase reversed apnea,
desaturation and loss of pulse and prevented mortality. Use of
BChE may provide an additional tool to increase the safety of
succinylcholine in emergent intubation.
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